A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
|Articles|October 28, 2021
Daily OTC Pearl: Tussin DM (Dextromethorphan and Guaifenesin)
Author(s)Saro Arakelians, PharmD
Tussin DM helps loosen phlegm and thin bronchial secretions to help drain bronchial tubes.
Advertisement
OTC/Lifestyle Pearl of the Day: Tussin DM (dextromethorphan and guaifenesin)
Indication: Tussin DM is used to treat cough and chest congestion caused by minor throat and bronchial irritations, the
Insight:
- Tussin DM helps loosen phlegm (mucus) and thin bronchial secretions to help drain bronchial tubes.
- Tussin DM will not treat a cough that is caused by
smoking . - Do not use Tussin DM if you have used an
MAO inhibitor in the past 14 days, such asisocarboxazid ,linezolid ,methylene blue injection,phenelzine ,rasagiline ,selegiline , ortranylcypromine . - Dosing: The recommended dose of Tussin DM is 10 ml every 4 hours for adults and children 12 years of age and older. Do not take more than 6 doses in any 24-hour period. Tussin DM is not intended for use in children under 12 years of age.
- Adverse effects may include mood changes, severe headache, dizziness, anxiety, drowsiness, sleep problems, insomnia, diarrhea, and feeling nervousness.
Sources:
Advertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5